BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 04 ott, 2016
    Axxam and Mercachem Sign a Strategic Alliance for Integrated Drug Discovery Services
    Molmed:  the European Commission grants a Conditional Marketing Authorisation to Zalmoxis®, the first immunogene therapy for the treatment of adult patients with high-risk haematological malignancies
    Genenta Science, Amgen, Ospedale San Raffaele deal
    Bio-on: nanotechnologies and bioplastic to diagnose and combat tumours
  • 25 lug, 2016
    Zambon lauches Xadago® (safinamide) in the Netherlands for patients with mid-to-late-stage Parkinson’s Disease
    MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis®
    Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
    Kedrion Biopharma consolidates presence on Russian Market
  • 17 giu, 2016
    Advanced Accelerator Applications Expands U.S. NETSPOT™ Supply Chain with Two Additional Radiopharmacy Networks
    The European Commission grants the European marketing authorisation to StrimvelisTM, GSK’s stem cell therapy for ADA-SCID patients
    FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with PBC
    Nouscom concludes successful series A financing of EUR 12 million
  • 25 mag, 2016
    Zambon launches XADAGO® (Safinamide) in the U.K. for patients with mid- to late-stage Parkinson’s Disease 
    Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy – Company provides update on key European production site
    Axxam expands to U.S., opens office in Cambridge, Mass.
    Revolution in food packaging. The milk carton goes bio 
  • 12 apr, 2016
    Ongoing Phase II Study of Evenamide (NW-3509) May Suggest an Alternative Approach to the Treatment of Schizophrenia
    GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID 
    Diasorin Shopping in USA
    MolMed and Genenta Science sign a collaboration agreement in the field of gene therapy for the treatment of tumors 
    Menarini announces the founding of Vaxynethic, joint venture with Biosynth
  • 08 mar, 2016
    World’s first material formulations laboratory to make MINERV PHAs advanced bioplastic 
    Drug Discovery Collaboration between Grünenthal and Axxam
    Zambon Launches Xadago® (Safinamide) In Italy For Patients With  Mid- To Late-Stage Parkinson’s Disease 
    Axxam and the NEOMED Institute to Collaborate on the Discovery and Development of a Novel Drug to Treat Metabolic Diseases 
  • 09 feb, 2016
    Kedrion Biopharma strengthens its position on the US Market
    AbbVie invests in Italy: 60 million dollars in arrival to the manufacturing site
    Zambon launches Xadago® (Safinamide) in Switzerland for patients with parkinson’s disease
    BioInItaly Investment Forum 2016, where biotech meets investors. 19-20 April in Milan
  • 08 gen, 2016

    The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major
    Science Translational Medicine published results of a study highlighting the role of memory stem T cells in the treatment of leukaemia
    Axxam and the Neurodegeneration Consortium at The University of Texas MD Anderson Cancer Center collaborate on a novel approach to Alzheimer’s disease research
    EryDel Consortium Gains € 6 million of EU Funding for Development of EDS  for the treatment of Ataxia Telangiectasia
    Capital Increase of  Flowmetric Europe
    Bioplastic created for the toys of the future safe and eco-sustainable, child-friendly and environmentally sound

  • 03 dic, 2015
    MolMed: AIFA granted authorization to manufacture gene therapies for marketing purposes
    Newron Completes 5.4 Million USD/CHF Private Placement with U.S. Biotechnology/Healthcare Specialist Fund
    Advanced Accelerator Applications S.A. listed on the US Nasdaq stock Exchange
    Newron initiates U.S. Phase II trial in patients with schizophrenia 
  • 02 nov, 2015
    Axxam executes agreement with NYU Langone Medical Center for the provision of drug discovery services
    Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment
    Meiji announces initiation of Phase II/III and long-term clinical trials of safinamide inhibitor developd by Newron Pharmaceuticals S.p.A. for the treatment of Parkinson’s disease
    BioInItaly Investment Forum 2016, where biotech meets investors. 19-20 April in Milan
  • 02 ott, 2015
    International award for Bioindustry Park/bioPmed Cluster
    Agreement to realise the first France-based facility for producing PHAs biopolymers from sugar beet co-products
    Xadago® (safinamide) New Drug Application - Late-Cycle Review Meeting Completed with U.S. FDA
    Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome
    Boston-based Angus signed a €40M deal with the Italian Biotech Diatheva to Immuno-oncology Target CEACAM1
  • 03 ago, 2015
    Long term benefit of erythrocyte-delivered dexamethasone in Ataxia Telangiectasia
    TLS Bio-incubator “doubling”. New spaces and labs available for public and private open access research
    Axxam enters into a research collaboration with The University of Texas MD Anderson Cancer Center for Assay Development and High Throughput Screening of selected targets in oncology
    Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome
    Axxam SpA enters into a collaboration agreement with Bayer HealthCare for the provision of Drug Discovery Services